Zynaxis surprise victim of Lilly cuts

Zynaxis Inc. has became the latest company to come under the ax as Eli Lilly and Co. continues to reevaluate its collaborative programs.

Lilly gave notice that it would terminate in August a 1992 agreement to apply ZNXS' drug delivery technology and Lilly's catheter device systems to vascular drugs. The goal of the collaboration was to reduce the rate of restenosis after